ImmunityBio, Inc. (IBRX) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 San Diego, CA, 미국. 현재 CEO는 Richard Gerald Adcock.
IBRX 을(를) 보유 IPO 날짜 2015-07-28, 671 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $7.81B.
ImmunityBio, Inc. is a clinical-stage biotechnology company headquartered in San Diego that develops immunotherapies and vaccines for cancer and infectious diseases. The company's pipeline includes advanced immunotherapy and cell therapy platforms, featuring antibody-cytokine fusion proteins, synthetic immunomodulators, natural killer cells, and T cell therapies, with multiple candidates in Phase II and III clinical trials for liquid and solid tumors such as bladder, pancreatic, and lung cancers, as well as viral pathogens including SARS-CoV-2 and HIV. ImmunityBio has established strategic partnerships with leading research institutions including the National Cancer Institute and collaboration or licensing agreements with multiple biotechnology and healthcare organizations to advance its therapeutic pipeline.
